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Background: Metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM) have been associated with
insulin-resistance; however, the effective therapies in improving insulin sensitivity are limited. This study is aimed at
investigating the effect of Guava Leaf (GL) extracts on glucose tolerance and insulin resistance in SHRSP.Z-Leprfa/
Izm rats (SHRSP/ZF), a model of spontaneously metabolic syndrome.
Methods: Male rats at 7 weeks of age were administered with vehicle water or treated by gavage with 2 g/kg GL
extracts daily for six weeks, and their body weights, water and food consumption, glucose tolerance, and insulin
resistance were measured.
Results: Compared with the controls, treatment with GL extracts did not modulate the amounts of water and
food consumption, but significantly reduced the body weights at six weeks post treatment. Treatment with GL
extracts did not alter the levels of fasting plasma glucose and insulin, but significantly reduced the levels of plasma
glucose at 60 and 120 min post glucose challenge, also reduced the values of AUC and quantitative insulin
sensitivity check index (QUICKI) at 42 days post treatment. Furthermore, treatment with GL extracts promoted IRS-1,
AKT, PI3Kp85 expression, then IRS-1, AMKP, and AKT308, but not AKT473, phosphorylation, accompanied by
increasing the ratios of membrane to total Glut 4 expression and adiponectin receptor 1 transcription in the
skeletal muscles.
Conclusions: These data indicated that GL extracts improved glucose metabolism and insulin sensitivity in the
skeletal muscles of rats by modulating the insulin-related signaling.Background
The incidence of metabolic syndrome (MS) and type 2
diabetes mellitus (T2DM) is increasing worldwide [1,2].
MS and T2DM are mediated by insulin-resistance. Hence,
therapeutic strategies for the intervention of MS and
T2DM should center on the improvement of insulin
sensitivity. Currently, the efficacy of available medicines
in improving insulin sensitivity is limited. Therefore, the
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reproduction in any medium, provided the orinsulin sensitivity and understanding their therapeutic
actions will be of great significance.
The skeletal muscles are important for glucose metabol-
ism, particularly in individuals with insulin resistance [3].
Physiologically, insulin can bind to its receptor and lead to
IR tyrosine kinase activation, which phosphorylates the
downstream IR substrate family members, such as IRS-1.
Subsequently, the activated IRS-1 can activate a cascade
of phosphorylation-dephosphorylation reactions, includ-
ing 85-kDa of phosphatidylinositol-3-kinase (PI3K-p85)
and serine/threonine kinases Akt/PKB (e.g. Ser-473 and
Thr-308 for the Akt/PKB isoform), leading to glucose
transporter 4 (GLUT4) translocation and intracellular
glucose metabolism [4]. Indeed, the multiple post-receptor
intracellular defects, such as activation of the insulin-
stimulated IRS/PI3K pathway, occur in the skeletal muscles. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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IRS/PI3K signal pathway in the skeletal muscles is a
promising therapeutic target in the effective treatment
of MS and T2DM.
Obesity is associated with the development of MS or
T2DM [6] and can promote excess deposition of lipids in
the muscle and liver, contributing to the development of
insulin resistance. Adiponectin is an adipocyte-secreted
adipokine [7] that can regulate insulin resistance, obesity,
and T2DM [8]. Adiponectin, through its receptor, can
activate the 50-AMP-activated protein kinase (AMPK) in
the skeletal muscles, which further stimulates the phos-
phorylation of acetyl coenzyme A carboxylase (ACC),
fatty-acid oxidation, glucose uptake, and reduction of
glucose levels. Therefore, up-regulation of adiponectin
receptor expression and activation can activate the
AMPK pathway and positively regulate glucose metab-
olism and insulin sensitivity in the skeletal muscles.
Guava Leaf (GL) has been widely used as a herbal
medicine for diabetes patients in some countries [9,10].
GL extracts contain tannins, polyphenolic compounds,
flavonoids, pentacyclic triterpenoids, guiajaverin, quercetin,
and other chemical compounds, which could regulate
hyperglycemia [11]. Indeed, GL extracts could inhibit
the PTP1B activity and alpha-glucosidase enzymes to
regulate glucose metabolism in db/db mice. Addition-
ally, it could promote glucose uptake in hepatocytes
and increase the activities of hepatic hexokinase and
glucose-6-phosphate dehydrogenase in the liver of STZ-
induced diabetic SD rats [12-15]. However, little is known
about whether GL extracts can modulate glucose metabol-
ism and insulin resistance in the skeletal muscles and
their mechanisms.
SHRSP.Z-Leprfa/Izm (SHRSP/ZF) rats were derived by
crossing the spontaneously hypertensive stroke-prone
Izumo rats (SHRSP/Izm) with Zucker fatty rats to gener-
ate a genetic mutant in the fa locus of chromosome 5. The
SHRSP/ZF rats spontaneously developed hyperglycemia,
obesity, hyperleptinemia, hypertension, and other meta-
bolic disorders, which resemble human MS [16]. This
strain of rats has been used as an excellent model of MS
for testing anti-diabetic natural products and determining
their therapeutic mechanisms.
We hypothesized that GL extracts may play a role in
improving insulin resistance via skeletal muscle, not just
through the liver. Thus, in this study, we investigated
the effects of oral treatment with the soluble GL ethanol
extracts on glucose metabolism and insulin resistance in
the skeletal muscles of SHRSP/ZF rats.
Methods
Plant materials
Guava Leaf (Folium Psidii Guajavae Psidium guajava L.)
was purchased from Sichuan Medical Pharmaceutical,Chengdu, China, and identified botanically by Pro.
Chunsheng Liu (School of Chinese Material Medica,
Beijing University of Chinese Medicine, Beijing, China).
A voucher specimen (No. 2009051603) was deposited
in the Experimental Center of Beijing University of
Chinese Medicine.
Preparation of plant extraction
Ethanolic extracts were isolated using a modified previ-
ously reported method [17]. The air-dried powdered leaves
of guava (5 kg) were extracted with 20 L of 70% (V/V)
ethanol three times at room temperature for 2 h with
reflux condenser. The extracts were combined and
concentrated by a rotary evaporator (Büchi, Rotavapor
R-215, Switzerland) to form a syrup under reduced pres-
sure (45°C). Subsequently, the syrup was evaporated to
dryness at 70°C in vacuo. Finally, the dried extract was
grounded to pass through a 60-mesh filter, and approxi-
mately 0.92 kg powder was obtained.
Animals
Male SHRSP/ZF rats at 6 weeks of age were obtained from
Japan SLC (Shizuoka, Japan). All rats were housed in a
specific pathogen-free facility with 22-24°C temperature,
40-60% humidity, 12-hour light and dark cycle, and
free access to normal chow and water for one week at
the School of Pharmaceutical Sciences of Mukogawa
Women’s University. SHRSP/ZF rats were randomized
and administered twice per day as follows: the experi-
mental group with GL extracts (2 g/kg) by gavage for
six weeks, which was made freshly and suspended in
distilled water (10 ml) before each oral administration;
and the control group with an equimolar solution of
distilled water.
The rats used in the present study were maintained
in accordance with guidelines of the care and use of
animals in the field of physiological sciences established
by the Physiological Society of Japan, and the study
was approved by the ethics committee of Mukogawa
Women’s University, which consisted of Prof. Semma M,
Shinozuka K, Moriyama K, Miki T, Ikeda K, Nakamura K,
Tanaka T, and Oku K.
Measurement of fasting plasma glucose, oral glucose
tolerance test, plasma insulin, triglycerides, cholesterol,
and FFA
Rats were fasted overnight, and their fasting blood glu-
cose levels were measured on day 0, 14, 28, and 42 post
treatment using One-touch meter [18]. At the end of the
experiment, blood samples were obtained from individ-
ual rats for the measurements of the concentrations of
fasting plasma insulin, triglycerides, cholesterol, and free
fatty acids (FFA).
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tolerance test (OGTT) on day 28 and 42 post treatment.
Briefly, after measuring fasting blood glucose levels, indi-
vidual rats were administered orally with 2 g/kg BW of
glucose and their blood glucose levels were measured
at 30, 60, 90, and 120 min post glucose challenge. The
area under the curve (AUC) over the levels of blood
glucose in individual rats was calculated by the trapezoidal
rule: {[15 × log(gluc0min)] + [30 × log(gluc30min)] + [45 ×
log(gluc60min)] + [30 × log(gluc120min)]/120} [19]. The
quantitative insulin sensitivity check index (QUICKI) of
individuals was calculated by (QUICKI = 1/[log(fasting -
insulin μU/ml) + log (fastin glucose mg/dl)]) [20].
Biochemical assays
The concentrations of plasma insulin and FFA were assayed
using specific ELISA kits (Wako Pure Chemical Industries,
Osaka, Japan). The concentrations of plasma triglycerides
and cholesterol were determined by regular biochemistry
assays using specific kits (Wako Pure Chemical Industries)
on an AU400 Biochemical Analyzer (Olympus, Japan).
Western blot analysis
The skeletal muscle tissues were collected from individ-
ual rats and subjected to lysis. After quantification, the
lysates were separated by SDS-PAGE and transferred
onto PVF membranes. Subsequently, the membranes
were blocked with 3% BSA and incubated with primary
antibodies against IRS-1, PI3K-p85, Akt, AMPK-α, GLUT4,
phosphorylated IRS-1, Akt 473, Akt 308, AMPK-α, and
control β-actin (Cell Signaling Technology, Beverly, MA,
USA). The bound antibodies were detected with HRP-
conjugated second antibodies and visualized using the
electrochemilluminescence kit (Amersham, UK). The rela-
tive levels of each target protein to control β-actin were
determined by densitometry analysis using the Image J 6.0
(Media Cybernetics). Additional Western blot assays were
performed for the characterization of membrane-associated
GLUT4 on the purified muscle membrane samples.
Quantitative RT-PCR
Total RNA was extracted from the skeletal muscle
tissues using Sepasol-RNA I Super G (Nacalai Tesque,
Kyoto) and reversely transcribed into cDNA using the
ReverTra Ace qPCR RT Kit (Toyobo), according to
the manufacturers’ instructions. The relative levels of
adiponectin receptor-1 mRNA transcripts to control
β-actin were determined by quantitative RT-PCR using
THUNDERBIRD SYBR qPCR Mix and specific primers
on the ABI Prism 7000. The sequences of primers
were forward 50TGAGGTACCAGCCAGATGTC30 and re-
verse 50CGTGTCCGCTTCTCTGTTAC30 for adiponectin
receptor-1 and forward 50GGGAAATCGTGCGTGACATT30
and reverse 50GCGGCAGTGGCCATCTC30 for β-actin.The data are expressed as the relative ratios of adiponectin
receptor-1 to β-actin.Statistical analysis
Data are expressed as the mean ± S.D. The difference
between groups was analyzed by Student’s t-test and
ANOVA for repeated measures. A P value of less than
0.05 was considered statistically significant.Results
GL extracts improve the glucose metabolism but do not
affect insulin production in SHRSP/ZF rats
To determine whether the GL extracts could affect glu-
cose metabolism, SHRSP/ZF rats were fed with water as
the controls or with GL extracts (2 g/kg) in water for six
weeks. The body weights and the amount of food and
water consumption of individual rats were measured in
Figure 1. While the body weights in the controls
increased with time, the body weights in the GL-treated
rats at 2 and 4 weeks post treatment were slightly lower
than that of the controls. The body weights in the GL-
treated rats at 6 weeks post treatment were significantly
lower than that of the controls (418.00 ± 12.98 vs.
385.00 ± 22.67 g, p = 0.01 n = 6) (Figure 1A). However,
there was no significant difference in the amount of
water and food consumption between the control and
GL-treated rats (Figure 1B and C). Next, the levels of
fasting blood glucose, oral glucose tolerance, and fasting
plasma insulin in individual rats were tested longitudin-
ally. There was no significant difference in the levels
of fasting blood glucose between the controls and GL-
treated rats before treatment and on day 14, 28 (data
not shown), and 42 post treatment (Figure 1D). While
there was no significant difference in the dynamics of
blood glucose levels following oral glucose challenge
on day 28 post treatment between the controls and
GL-treated rats, the levels of blood glucose at 60
(204.18 ± 11.34 vs. 168.07 ± 9.15 mg/dl, p = 0.04, n = 6)
and 120 minutes (153.62 ± 6.37vs. 121.83 ± 11.27 mg/dl,
p = 0.03, n = 6) post glucose challenge on day 42 in the
GL-treated rats were significantly lower than that in the
controls (Figure 1E). As a result, the values of the AUC
over the first 2-h after glucose challenge (GAUC0-2) in
the GL-treated rats were significantly less than that of
the controls (210.53 ± 5.15 vs. 203.08 ± 4.33 mg/dl/min,
p = 0.02, n = 6, Figure 1G), and the QUICKI values in
the GL-treated rats were significantly less than that in
the control rats (3.40 ± 0.28 vs. 3.01 ± 0.12, p = 0.04,
n = 6, Figure 1H). However, there was no significant dif-
ference in the levels of fasting plasma insulin (Figure 1F),
FFA (Figure 1I), fasting plasma triglyceride, and choles-
terol (data not shown) between the controls and GL-
treated rats at 6 weeks post treatment.
Figure 1 The effects of GL extracts on the body weights and glucose tolerance in rats. Male SHRSP/ZF rats at 7-weeks of age were
administered with vehicle water or treated by gavage with 2 g/kg GL extracts daily for six weeks. Their body weights (A) and the amount of food
(B) and water (C) consumption of individual rats were measured longitudinally before and after treatment. The levels of fasting blood glucose (D),
oral glucose tolerance (E), fasting plasma insulin (F), GAUC0-2 (G), QUICKI (H), and FFA (I) at 6 weeks post treatment were measured. Data are
expressed as the mean ± S.D. of individual groups of rats (n = 6 per group). * p < 0.05 vs. the control group.
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muscles by promoting the IRS-1-PI3K signal pathway in
SHRSP/ZF rats
Insulin binds to its receptor, which phosphorylates the
insulin receptor substrate (IRS)-1 and activates the PI3K
pathway [21]. We tested whether GL extracts might
improve insulin sensitivity in rats and characterized the
levels of IRS-1 phosphorylation and PI3K in the skeletal
muscles of different groups of rats by Western blot assays.
The levels of IRS-1 (0.48 ± 0.25 vs. 0.98 ± 0.23, p = 0.02,
n = 4, Figure 2A and B), phosphorylated IRS-1 (0.23 ±
0.11 vs. 0.54 ± 0.16, p =0.02, n = 4, Figure 2A and C),
and PI3K-p85 (1.02 ± 0.13 vs. 1.29 ± 0.16, p = 0.03, n = 4,
Figure 2A and D) in the muscles from the GL-treated
rats were significantly higher than that in the controls.
These data indicate that treatment with GL extracts
significantly improved insulin sensitivity of the muscles
in rats.Activation of the PI3K pathway can further activate
the protein kinase B/Akt pathway, which is a central
intermediate for the metabolic actions of insulin [22].
We measured the relative levels of Akt, phosphorylated
Akt 308, and Akt 473 in the muscles of rats, respectively.
As shown in Figure 2, the relative levels of total Akt
(0.44 ± 0.09 vs. 0.84 ± 0.11, p = 0.001, n = 4, Figure 2E and
F) and phosphorylated Akt 308 (0.29 ± 0.17 vs. 0.74 ± 0.10,
p = 0.005, n = 4, Figure 2E and G), but not Akt 473
(Figure 2E and H) in the muscles form the GL-treated rats
were significantly higher than that in the controls. Finally,
we found that similar levels of total GLUT4 were detected
in the muscles from both groups of rats and that the levels
of membrane-associated GLUT4 in the muscles from
the GL-treated rats were obviously higher than that in
the controls. As a result, the relative ratios of membrane-
associated GLUT4 to total GLUT4 in the muscles form
the GL-treated rats were significantly greater than that in
Figure 2 The effects of GL extracts on skeletal muscles IRS-PI3k signaling in rats. After the end of treatment, the levels of IRS-1 (A and B),
phosphorylation IRS-1 (A and C), PI3K-p85 (A and D), Akt (E and F), phosphorylation Akt 308 (E and G), and Phosphorylation Akt 473 (E and H) in
the skeletal muscles, as well as the membrane and total GLUT4 (I and J) in the skeletal muscles were characterized by Western blotting. Data are
representative images or expressed as the mean ± S.D. of individual groups of rats (n = 4 per group). * p < 0.05 vs. the control group.
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Figure 2I and J). Therefore, treatment with GL extracts
enhanced insulin-mediated GLUT4 translocation on the
plasma membrane of muscle cells, leading to the improve-
ment of insulin sensitivity.GL extracts improve the adiponectin receptor-1 gene
expression in the skeletal muscles
Low levels of plasma adiponectin are associated with
the development of obesity and T2DM as well as
hyperlipideamia [23]. Furthermore, elevated levels of
triglyceride and FFA can interfere with insulin sensi-
tivity in the muscles [24]. To further elucidate the
mechanisms underlying the action of GL extracts, we
characterized the relative levels of adiponectin recep-
tor mRNA transcripts in the skeletal muscles from
different groups of rats by quantitative RT-PCR. We
found that the relative levels of adiponectin receptor-1
(AdipoR1) mRNA transcripts in the muscles from the
GL-treated rats were significantly higher than that in
the controls (0.56 ± 0.07 vs. 1.37 ± 0.31, p = 0.02, n = 4,
Figure 3A).GL extracts improve the AMPK phosphorylation in the
skeletal muscles
Dysregulation of fatty acid metabolism plays a pivotal
role in the pathogenesis of insulin resistance in the
skeletal muscle [25]. Adiponectin can activate the
AMPK, which is crucial for glucose and lipid metabol-
ism in the skeletal muscles. Finally, we examined the
levels of AMPK activation in the muscles of different
groups of rats and found that the relative levels of
phosphorylated AMPK to total AMPK in the muscles
form the GL-treated rats were significantly higher than
that in the controls (0.37 ± 0.05 vs.1.71 ± 0.77, p = 0.04,
n = 4, Figure 3B and C). These data indicated that treat-
ment with GL extracts enhanced the AMPK activation,
which may reduce the body weights and improvement
of insulin sensitivity in rats.Figure 3 The effect of GL extracts on skeletal muscles AdipoR1 expre
AdipoR1 mRNA transcripts were determined by RT-PCR, and the levels of t
rats were characterized by Western blot assays. Data are representative image
group). (A) RT-PCR analysis of the AdipoR1 mRNA transcripts and (B and C) W
vs. the control group.Discussion
In a previous study, we demonstrated that administra-
tion of GL extracts may have preventive effects of
ameliorating hepatic accumulation and hepatic insulin
resistance by enhancing the adiponectin β-oxidation
system [26]. However, studies have yet to elucidate
the underlying mechanisms of GL extracts on glucose
metabolism and insulin resistance in skeletal muscle.
This study was designed to investigate the effects of
the ethanol soluble GL extracts on glucose tolerance and
insulin sensitivity in the skeletal muscles of SHRSP/ZF
rats. We found that oral treatment with GL extracts for
six weeks did not alter in the amount of food and water
consumption and fasting plasma glucose and insulin
levels in SHRSP/ZF rats. However, the treatment did
significantly improve glucose tolerance in the rats. Evi-
dentially, the levels of plasma glucose at 60 and 120 min
post glucose challenge in the GL-treated rats at 42 days
post treatment were significantly lower than that in the
control rats. As a result, the values of AUC and QUICKI
in the GL-treated rats were significantly less than that
in the control rats. These data suggest that GL extracts
may enhance glucose challenge-stimulated insulin secre-
tion, which promotes glucose metabolism and improves
insulin sensitivity in the major glucose metabolic organs,
such as the skeletal muscles, liver, and adipose tissues of
SHRSP/ZF rats [27].
Obviously, the skeletal muscle is the main organ re-
sponsible for the postprandial hyperglycemia following
a meal in normal individuals. Given that previous stud-
ies have demonstrated that treatment with GL extracts
could stimulate glucose utilization in liver tissues in
spontaneous and inducible animal models of diabetes
[12-15], our data extended previous findings and indicated
that treatment with GL extracts improved glucose tolerance
and insulin sensitivity in the skeletal muscles of animals.
Insulin can interact with its receptor and activate IR
tyrosine kinase, leading to the activation of IRS-1, PI3K-
p85, AKT, and GLUT4 translocation, and promoting
glucose uptake and metabolism in the skeletal musclesssion and AMPK phosphorylation in rats. The relative levels of
otal AMKP expression and phosphorylation in the muscles of individual
s or expressed as the mean ± S.D. of individual groups of rats (n = 4 per
estern blot analysis of AMKP expression and phosphorylation. * p < 0.05
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events is associated with the development of insulin re-
sistance and glucose intolerance [5,25]. To understand
the mechanisms underlying the action of GL extracts in
regulating glucose metabolism, we characterized the
levels of insulin-related signaling in the skeletal muscles.
We found that treatment with GL extracts significantly
promoted IRS-1, AKT, PI3Kp85 expression and IRS-1,
AMKP, and AKT308, but not AKT473, phosphorylation
in the skeletal muscles of SHRSP/ZF rats. These data
indicated that treatment with GL extracts promoted
insulin-related signaling in the skeletal muscles of SHRSP-
ZF rats. The enhanced insulin-related signaling should
enhance GLUT4 translocation in the muscular cells.
Indeed, we found that treatment with GL extracts sig-
nificantly increased the ratio of membrane to total
GLUT4 expression in the skeletal muscles of SHRSP-
ZF rats. Conceivably, the increased membrane-related
GLUT4 should enhance glucose uptake and accelerate
glucose metabolism in the skeletal muscles of SHRSP/
ZF rats. Given that insulin resistance is a pathological
hallmark of MS and T2DM, the activity of GL extracts
in improving insulin sensitivity in the skeletal muscles
suggest that GL extracts may be valuable for the con-
trol of insulin resistance-related MS and T2DM.
Obesity is associated with the development of insulin
resistance and T2DM [29]. In T2DM and obese individuals,
insulin-stimulated glucose disposal in skeletal muscle
is markedly impaired, because excess fat can deposit
and accumulate in the myocytes, impairing insulin
sensitivity [30]. The altered fatty acid metabolism in
the muscles is also observed in obese Zucker rats and
is associated with the development of insulin resist-
ance [31]. In our study, we found that treatment with
GL extracts for six weeks significantly reduced the
gain of body weight in SHRSP/ZF rats. Given that the
loss of body weight in obese individuals can improve
insulin sensitivity [32], the effect of GL extracts on sig-
nificantly reduced body weights may also contributes to
its activity in the improvement of insulin resistance in the
skeletal muscles of SHRSP/ZF rats. Notably, obesity is a
risk factor of the development of MS, T2DM, and hyper-
tension as well as other cardiovascular diseases. Therefore,
GL extracts may be beneficial for obese individuals to
prevent and treat MS, T2DM, and hypertension.
Adiponectin is an adipokine and insufficient adiponectin
has been implicated in the development of obesity and
T2DM [8]. AdipoR1 is abundantly expressed in skeletal
muscle and at moderate levels in other tissues, whereas
AdipoR2 is predominantly expressed in the liver [7]. In
previous study, we demonstrated that GL extracts signifi-
cantly decrease liver triglyceride content of SHRSP/ZF
rats via increase the AdipoR1 and AdipoR2 to active the
activity of AMPK and PPARα [26]. In present study,although we did not observe that treatment with GL
extracts significantly altered the levels of plasma lipids,
we found that the treatment significantly up-regulated
AdipoR1 expression and increased the AMKP activation
in the skeletal muscles of SHRSP-ZF rats. The enhanced
AMKP activation by GL extracts increased fatty acid
oxidation and decreased fatty acid esterification, inhibiting
ACC activity, and suppressing lipogenic enzymes, such as
fatty acid synthase and stearoyl CoA desaturase 1 [33],
which resulted in the reduction of fat deposition and ac-
cumulation in the skeletal muscles. This may contribute
to its activity in reducing body weight, ameliorating
IRS-PI3K-AKT signaling pathway to improve glucose
tolerance and insulin sensitivity in the skeletal muscles.
Furthermore, the enhanced AMKP activation may stimu-
late muscle glucose uptake, this occurs through a distinct
mechanism than the insulin-signaling pathway [34].Conclusions
In summary, our data indicated that oral treatment with
GL extracts reduced the gain of body weight and improved
glucose metabolism and insulin sensitivity in SHRSP/ZF
rats. Furthermore, we found that treatment with GL
extracts significantly enhanced the insulin-related sig-
naling, GLUT4 translocation, AdipoR1 expression, and
AMKP activation in the skeletal muscles of SHRSP/ZF
rats. It is possible that GL extracts, through activating
the insulin signaling and promoting glucose metabolism
and fatty acid oxidation, lead to the improvement of
insulin sensitivity in the skeletal muscles in SHRSP/ZF
rats. Therefore, our findings may provide new insights
into the mechanisms by which GL extracts inhibit in-
sulin resistance in the skeletal muscles. Potentially, our
findings may aid in the design of new therapies for the
prevention and treatment of insulin resistance-related
MS, T2DM, and hypertension in the clinic.
Abbreviations
MS: Metabolic syndrome; T2DM: Type 2 diabetes mellitus; IRS: Insulin
receptor substrate; PI3K: Phosphatidylinositol-3-kinase; PKB/AKT: Protein
kinase B; GLUT 4: Glucose transporter 4; AMPK: 50-AMP-activated protein
kinase; ACC: Acetyl coenzyme A carboxylase; GL: Guava leaf; PTP1B: Protein
tyrosine phosphatase 1B; SHRSP/ZF: SHRSP.Z-Leprfa/Izm; FFA: Free fatty acids;
OGTT: Oral glucose tolerance test; AUC: Area under the curve;
QUICKI: Quantitative insulin sensitivity check index.
Competing interests
The authors declare no financial or commercial conflicts of interest.
Authors’ contributions
XG designed the study, conducted the experiments, and wrote the
manuscript. YH performed the experiments, analyzed the data. GM designed
the study and wrote the manuscript. YD, WS, TX, and PX performed the
experiments and analyzed the data and manuscript preparation. LQ and JZ
helped to perform the experiment. LH drafted the manuscript. TL provided
the initial idea, instructed the study, and wrote the manuscript. All authors
read and approved of the final manuscript.
Guo et al. BMC Complementary and Alternative Medicine 2013, 13:52 Page 8 of 8
http://www.biomedcentral.com/1472-6882/13/52Acknowledgements
This study was supported by grants from the Program for Innovative
Research Team of Beijing University of Chinese Medicine (No.2011-CXTD-19),
the Cooperation Program of Beijing Municipal Commission of Education
(No.2011-BJSGJ), the International Scientific Collaborative Project
(No.2009DFA31520), the Young Scholars of Ph.D. Programs Foundation of
Ministry of Education of China (No. 20120013120012), and the Independent
Research Project of Beijing University of Chinese Medicine. The authors thank
Health-cultivation Laboratory of the Ministry of Education of China for
experimental technical support.
Author details
1Department of Endocrinology, Dongfang Hospital of Beijing University of
Chinese Medicine, No.6, 1st Area Fangxing Yuan, Fangzhuang Fengtai
District, Beijing 100078, China. 2School of Pharmaceutical Sciences of
Mukogawa Women’s University, 11-68 Koshien-Kyuban-cho, Nishinomiya
663-8179, Hyogo, Japan. 3Department of Chinese Medicine, Tongren Hospital
of Capital Medical University, No.2, Chongwenmennei Street, Dongcheng
District, Beijing 100730, China. 4Department of Science and Technology,
Beijing University of Chinese Medicine, No.11, North 3rd-ring East Road, Chao
Yang District, Beijing 100029, China.
Received: 28 August 2012 Accepted: 25 February 2013
Published: 1 March 2013References
1. Ford ES: Prevalence of the metabolic syndrome defined by the
international diabetes federation among adults in the U.S. Diabetes Care
2005, 28(11):2745–2749.
2. Zheng Y, Stein R, Kwan T, Yu C, Kwan J, Chen S-l, Hu D: Evolving
cardiovascular disease prevalence, mortality, risk factors, and the
metabolic syndrome in China. Clin Cardiol 2009, 32(9):491–497.
3. Defronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J: Effects of
insulin on peripheral and splanchnic glucose metabolism in noninsulin-
dependent (type II) diabetes mellitus. J Clin Invest 1985, 76(1):149–155.
4. White MF: IRS proteins and the common path to diabetes. Am J Physiol
Endocrinol Metab 2002, 283(3):E413–E422.
5. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T,
DeFronzo RA, Kahn CR, Mandarino LJ: Insulin resistance differentially
affects the PI3-kinase- and MAP kinase-mediated signaling in human
muscle. J Clin Invest 2000, 105(3):311–320.
6. Ginsberg HN, MacCallum PR: The obesity, metabolic syndrome, and type
2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease
risk and the importance of atherogenic dyslipidemia in persons with the
metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr
2009, 4(2):113–119.
7. Goldstein BJ, Scalia R: Adiponectin: a novel adipokine linking adipocytes
and vascular function. J Clin Endocrinol Metab 2004, 89(6):2563–2568.
8. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K,
Shimomura I, Nakamura T, Miyaoka K, et al: Paradoxical decrease of an
adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res
Commun 1999, 257(1):79–83.
9. Owen PL, Martineau LC, Caves D, Haddad PS, Matainaho T, Johns T:
Consumption of guava (Psidium guajava L) and noni (Morinda citrifolia
L) may protect betel quid-chewing Papua New Guineans against
diabetes. Asia Pac J Clin Nutr 2008, 17(4):635–643.
10. Ernst E: Plants with hypoglycemic activity in humans. Phytomedicine 1997,
4(1):73–78.
11. Ojewole JAO: Hypoglycemic and hypotensive effects of Psidium guajava
Linn. (Myrtaceae) leaf aqueous extract. Methods Find Exp Clin Pharmacol
2005, 27(10):689–695.
12. Oh WK, Lee CH, Lee MS, Bae EY, Sohn CB, Oh H, Kim BY, Ahn JS:
Antidiabetic effects of extracts from Psidium guajava. J Ethnopharmacol
2005, 96(3):411–415.
13. Cheng F-C, Shen S-C, Wu JS-B: Effect of guava (Psidium guajava L.) leaf
extract on glucose uptake in rat hepatocytes. J Food Sci 2009,
74(5):H132–H138.
14. Shen S-C, Cheng F-C, Wu N-J: Effect of guava (Psidium guajava Linn.) leaf
soluble solids on glucose metabolism in type 2 diabetic rats. Phytother
Res 2008, 22(11):1458–1464.15. Deguchi Y, Miyazaki K: Anti-hyperglycemic and anti-hyperlipidemic effects
of guava leaf extract. Nutr Metab 2010, 7:9.
16. Hiraoka-Yamamoto J, Nara Y, Yasui N, Onobayashi Y, Tsuchikura S, Ikeda K:
Establishment of a new animal model of metabolic syndrome: SHRSP
fatty (fa/fa) rats. Clin Exp Pharmacol Physiol 2004, 31(1–2):107–109.
17. Qian H, Nihorimbere V: Antioxidant power of phytochemicals from
Psidium guajava leaf. J Zhejiang Univ Sci 2004, 5(6):676–683.
18. Koch TR, Nipper HC: Evaluation of automated glucose oxidase methods
for serum glucose: comparison to hexokinase of a colorimetric and an
electrometric method. Clin Chim Acta 1977, 78(2):315–322.
19. van Hoek M, Langendonk JG, de Rooij SR, Sijbrands EJG, Roseboom TJ:
Genetic variant in the IGF2BP2 gene may interact with fetal malnutrition
to affect glucose metabolism. Diabetes 2009, 58(6):1440–1444.
20. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ:
Quantitative insulin sensitivity check index: a simple, accurate method
for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000,
85(7):2402–2410.
21. Boura-Halfon S, Zick Y: Phosphorylation of IRS proteins, insulin action, and
insulin resistance. Am J Physiol Endocrinol Metab 2009, 296(4):E581–E591.
22. Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB: Normal insulin-
dependent activation of Akt/protein kinase B, with diminished activation
of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest
1999, 104(6):733–741.
23. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi
H, Kuriyama H, Ouchi N, Maeda K, et al: Plasma concentrations of a novel,
adipose-specific protein, adiponectin, in type 2 diabetic patients.
Arterioscler Thromb Vasc Biol 2000, 20(6):1595–1599.
24. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T,
Murakami K, Tsuboyama-Kasaoka N, et al: The fat-derived hormone
adiponectin reverses insulin resistance associated with both lipoatrophy
and obesity. Nat Med 2001, 7(8):941–946.
25. Abdul-Ghani MA, DeFronzo RA: Pathogenesis of insulin resistance in
skeletal muscle. J Biomed Biotechnol 2010, 2010:476279.
26. Yoshitomi H, Guo X, Liu T, Gao M: Guava leaf extracts alleviate fatty liver
via expression of adiponectin receptors in SHRSP.Z-Leprfa/Izm rats.
Nutr Metab (Lond) 2012, 9:13.
27. DeFronzo RA: Pathogenesis of type 2 diabetes mellitus. Medical Clinics of
North America 2004, 88(4):787–835. ix.
28. Shepherd PR, Kahn BB: Mechanisms of disease - glucose transporters and
insulin action - implications for insulin resistance and diabetes mellitus.
N Eng J Med 1999, 341(4):248–257.
29. Wedick NM, Snijder MB, Dekker JM, Heine RJ, Stehouwer CDA, Nijpels G, van
Dam RM: Prospective investigation of metabolic characteristics in
relation to weight gain in older adults: the Hoorn Study. Obesity 2009,
17(8):1609–1614.
30. Phillips DIW, Caddy S, Ilic V, Fielding BA, Frayn KN, Borthwick AC, Taylor R:
Intramuscular triglyceride and muscle insulin sensitivity: evidence for a
relationship in nondiabetic subjects. Metab Clin Exp 1996, 45(8):947–950.
31. Turcotte LP, Swenberger JR, Tucker MZ, Yee AJ: Increased fatty acid uptake
and altered fatty acid metabolism in insulin-resistant muscle of obese
Zucker rats. Diabetes 2001, 50(6):1389–1396.
32. Houmard JA, Pories WJ, Dohm GL: Is there a metabolic program in the
skeletal muscle of obese individuals? Journal of Obesity 2011, 2011:250496.
33. Shimabukuro M, Koyama K, Chen G, Wang M-Y, Trieu F, Lee Y, Newgard CB,
Unger RH: Direct antidiabetic effect of leptin through triglyceride
depletion of tissues. Proc Natl Acad Sci USA 1997, 94(9):4637–4641.
34. Viollet B, Lantier L, Devin-Leclerc J, Hebrard S, Amouyal C, Mounier R, Foretz
M, Andreelli F: Targeting the AMPK pathway for the treatment of Type 2
diabetes. Frontiers in bioscience: a journal and virtual library 2009,
14:3380–3400.
doi:10.1186/1472-6882-13-52
Cite this article as: Guo et al.: Guava leaf extracts promote glucose
metabolism in SHRSP.Z-Leprfa/Izm rats by improving insulin resistance
in skeletal muscle. BMC Complementary and Alternative Medicine 2013
13:52.
